Want to see HK:1302 full AI Analyst Report?
LifeTech Scientific Corporation (1302) AI Stock Analysis
LifeTech Scientific Corporation
(HKEX:1302)
The overall score reflects LifeTech’s strong financial profile, led by rapid revenue growth, high gross margins, and a pristine, low-leverage balance sheet, tempered by declining profitability metrics and capex-related cash flow variability. Technical indicators point to a modestly weak price trend without severe downside momentum, while a relatively high P/E and lack of dividend data indicate a valuation premium that slightly constrains the score.
LifeTech Scientific Corporation (1302) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 6.47B
- Dividend Yield
- ―
- Average Volume (3M)
- 19.19M
- Price to Earnings (P/E)
- 98.0
- Beta (1Y)
- 0.66
- Revenue Growth
- 0.75%
- EPS Growth
- -20.22%
- Country
- Hong Kong
- Employees
- 1,245
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
LifeTech Scientific Corporation Business Overview & Revenue Model
Company Description
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, Sou...
LifeTech Scientific Corporation Financial Statement Overview
Summary
Strong revenue growth and high gross margins, combined with an exceptionally low-debt balance sheet and solid cash generation, are offset by declining net margins, ROE, and capex-driven cash flow volatility.
Income Statement
82Very PositiveBalance Sheet
94Very PositiveCash Flow
76Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.29B | 1.37B | 1.30B | 1.27B | 1.10B | 925.33M |
| Gross Profit | 987.25M | 1.02B | 981.43M | 995.64M | 873.93M | 747.53M |
| EBITDA | 277.17M | 266.10M | 296.37M | 253.46M | 445.78M | 397.59M |
| Net Income | 58.41M | 147.83M | 222.39M | 263.24M | 325.34M | 292.47M |
Balance Sheet | ||||||
| Total Assets | 4.75B | 5.01B | 4.90B | 4.70B | 3.69B | 3.18B |
| Cash, Cash Equivalents and Short-Term Investments | 1.24B | 1.20B | 1.18B | 1.18B | 833.79M | 1.48B |
| Total Debt | 14.10M | 8.04M | 4.98M | 9.30M | 9.67M | 15.67M |
| Total Liabilities | 1.48B | 1.48B | 1.42B | 1.37B | 769.05M | 653.61M |
| Stockholders Equity | 3.32B | 3.51B | 3.49B | 3.37B | 2.90B | 2.50B |
Cash Flow | ||||||
| Free Cash Flow | 480.76M | 501.49M | 38.46M | 125.36M | 52.84M | 145.57M |
| Operating Cash Flow | 531.28M | 555.01M | 321.46M | 418.05M | 388.32M | 488.85M |
| Investing Cash Flow | 353.57M | -73.91M | -517.53M | -453.88M | -458.47M | -86.76M |
| Financing Cash Flow | -666.93M | -383.59M | -116.97M | 182.71M | -215.20M | -256.38M |
LifeTech Scientific Corporation Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1302, the sentiment is Positive. The current price of 1.57 is above the 20-day moving average (MA) of 1.46, above the 50-day MA of 1.40, and below the 200-day MA of 1.61, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 59.19 is Neutral, neither overbought nor oversold. The STOCH value of 56.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1302.
LifeTech Scientific Corporation Peers Comparison
Overall Rating
- HK:130274Outperform
HK:178972Outperform
HK:217267Neutral
HK:999646Neutral
HK:216043Neutral
HK:085341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1302 | 74Outperform | HKD 6.35B | 98.02 | 1.71% | ― | 0.75% | -20.22% |
| HK:1789 | 72Outperform | HKD 5.05B | 11.36 | 13.24% | 2.59% | 16.15% | 31.89% |
| HK:2172 | 67Neutral | HKD 4.71B | 21.26 | 10.38% | 1.74% | 3.83% | -27.04% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9996 | 46Neutral | HKD 2.55B | -15.11 | -7.65% | ― | 21.23% | 36.89% |
| HK:2160 | 43Neutral | HKD 1.63B | -0.86 | -6.69% | ― | ― | ― |
| HK:0853 | 41Neutral | HKD 11.65B | 31.23 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1302 | LifeTech Scientific Corporation | 1.57 | -0.40 | -20.30% | |
| HK:0853 | MicroPort Scientific Corp | 6.08 | -5.36 | -46.90% | |
| HK:9996 | Peijia Medical Ltd. | 3.78 | -1.99 | -34.49% | |
| HK:1789 | AK Medical Holdings Ltd. | 4.61 | -1.05 | -18.54% | |
| HK:2160 | MicroPort CardioFlow Medtech Corp. | 1.28 | -4.32 | -77.14% | |
| HK:2172 | MicroPort NeuroTech Limited | 8.05 | -3.29 | -29.02% |
LifeTech Scientific Corporation Corporate Events
LifeTech’s Bioresorbable Iliac Artery Scaffold Wins NMPA Innovative Device Fast-Track
LifeTech Scientific has secured admission of its ICS Elpis bioresorbable peripheral balloon-expandable covered scaffold system into China’s Special Examination and Approval Procedure for Innovative Medical Devices. The product, designed for tre...
LifeTech’s SureCham Aortic Arch Stent Graft Wins Fast-Track Approval Route in China
LifeTech Scientific has announced that its jointly developed SureCham Aortic Arch Single-Branch Stent Graft System has been accepted into China’s Special Examination and Approval Procedure for Innovative Medical Devices. The device, created wit...
LifeTech Valve System Wins Fast-Track Status in China
LifeTech Scientific has announced that its Lantval Aortic Valve Replacement System has been admitted into the National Medical Products Administration’s Special Examination and Approval Procedure for Innovative Medical Devices, marking the comp...
LifeTech Scientific Swings to Interim Loss on Revenue Decline and FX Hit
LifeTech Scientific Corporation reported interim revenue of RMB600.8 million for the six months ended 30 June 2026, down 11.2% year on year, with gross profit falling 6.4% to RMB465.9 million as weaker sales and lower cost of sales reshaped its margi...
LifeTech Scientific Flags Interim Loss on Lower Revenue and One-Off Costs
LifeTech Scientific has warned that its unaudited net profit attributable to shareholders for the six months ended 30 June 2026 is expected to fall sharply to about RMB110 million to RMB120 million, from RMB238.5 million a year earlier, mainly due to...
LifeTech Scientific Names New Authorised Representative After Board Change
LifeTech Scientific Corporation has appointed executive director Fang Yu as an authorised representative of the company under Hong Kong listing rules, effective 12 August 2026. This move follows the previously disclosed resignation of executive direc...
LifeTech Scientific Sets August Board Meeting for Interim Results and Dividend Review
LifeTech Scientific Corporation has scheduled a board meeting for 28 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026, and to authorise their publication on the Hong Kong stock exchange and the com...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 27, 2026